Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to be more efficient than its blockbuster drugs currently on the market, Ozempic and Wegovy.
Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss
Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 weeks in a Phase 1b/2a trial.
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Popular weight loss drugs could be cheaper for some Americans: What you need to know
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...
What’s Behind Explosive Reaction To Oprah’s Weight Loss Confession?
The media mogul's comments about weight loss drugs and "thin people" have stirred intense reactions across social media platforms.
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Benefits Pro1d
Challenges employers will face in 2025 with weight-loss drugs
The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...
Insurancenewsnet.com4h
Colorado plans to limit coverage of weight-loss drugs like Wegovy for state employees to save $17M
Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...